TG Therapeutics (TGTX) Misses Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to TG Therapeutics (TGTX) Misses Q2 EPS by 10c

Goldman Sachs Upgrades TG Therapeutics (TGTX) to Neutral, 'Valuation reflects Briumvi outlook'

August 2, 2023 7:09 AM EDT

Goldman Sachs analyst Corinne Jenkins upgraded TG Therapeutics (NASDAQ: TGTX) from Sell to Neutral with a price target of $12.00 (from $16.00).

The analyst comments "We upgrade TGTX to Neutral from Sell and lower our 12-month price target to $12 ($16 prior). TGTX shares closed -50% (vs. XBI -1.2%) following 2Q23 EPS, which included revenue of $16.0M, well... More

TG Therapeutics (TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI

August 1, 2023 7:28 AM EDT

TG Therapeutics (NASDAQ: TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI

... More